Salute e Benessere

FutureBridge Releases Tumor Report on the Future of NSCLC Treatment and Evolving…

Key insights are focused on: Key insights are focused on: FutureBridge acknowledges the crucial role of collaboration and competition in advancing NSCLC research. Through strategic partnerships with consortia like the Lung Cancer Research Foundation and the International Lung Cancer Consortium, combined efforts across academia and industry streamline research, accelerating progress and addressing NSCLC challenges. Expert Analysis: "Proposing strategic initiatives encompassing...
PR Newswire
02/05/2024

STALICLA initiates U.S. Phase 3 enabling DDI study of STP7 (Mavoglurant) to…

Geneva, Switzerland, May 2, 2024– STALICLA SA, a late-stage biotechnology company specializing in precision medicine for brain disorders, announces the First Patient First Visit (FPFV) for the company's drug-drug interaction (DDI) study of STP7 (Mavoglurant), an mGluR5 negative allosteric modulator, licensed to STALICLA by Novartis. The DDI study is the last regulatory requirement in a comprehensive Phase 2 program and completion is expected to trigger initiation of a Phase 3 study in the...
Nasdaq GlobeNewswire
02/05/2024

AMO Pharma Completes Meeting with U.S. FDA and Outlines Plans to Advance…

Results from AMO Pharma's previous REACH-CDM Phase 2/3 clinical study (the "REACH-CDM Study") involving children and adolescents with congenital-onset DM1 showed that AMO-02 was generally safe and well tolerated during the study, with no reported severe adverse events (SAEs) related to treatment. The primary and secondary outcome measures based on clinician administered subjective ratings showed an unexpected placebo effect that may have masked some beneficial effects of treatment…
PR Newswire
02/05/2024

Amolyt Pharma Granted FDA Fast Track Designation for Eneboparatide for the…

Designation reflects the seriousness of the disease and the potential for eneboparatide to address the urgent need for new treatment options that address key treatment goals in hypoparathyroidism “We believe FDA's granting of fast track designation to eneboparatide reflects the agency's recognition of the significant unmet needs that persist among patients suffering from hypoparathyroidism,” stated Thierry Abribat, Ph.D., founder and chief executive officer of Amolyt Pharma. “We look...
Nasdaq GlobeNewswire
02/05/2024

Sustainable Swimwear Market to Reach $16.2 Billion Globally by 2032 at 7.7%…

Download Sample Pages of Research Overview: https://www.alliedmarketresearch.com/request-sample/A323341 Download Sample Pages of Research Overview:https://www.alliedmarketresearch.com/request-sample/A323341 Prime Determinants of Growth The growing awareness of environmental impact, rising demand from the fashion industry, and the regulations & policies promoting sustainability are the factors expected to drive the growth of the global sustainable swimwear market in the...
PR Newswire
02/05/2024

Alvotech Announces Participation at BofA Securities Healthcare Conference 2024

Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, announced today that members of management would be participating in the upcoming BofA Securities Healthcare Conference 2024, which will be held on May 14-15, 2024 in Las Vegas, NV.Members of Alvotech's management team will be attending the conference and hosting one-on-one meetings with investors. About AlvotechAlvotech is a biotech company,...
Nasdaq GlobeNewswire
02/05/2024

Alkermes plc Completes Sale of Athlone, Ireland Facility to Novo Nordisk

Alkermes and Novo Nordisk also entered into subcontracting arrangements to continue certain development and manufacturing activities currently performed at the facility for a period of time after closing of the transaction, which activities may continue through the end of 2025. This transaction is expected to be operating cost-neutral to Alkermes over the subcontracting period, and thereafter, the transaction is expected to yield significant operating cost benefit and contribute to enhanced…
PR Newswire
02/05/2024

Pharmaceutical Warehousing Market to Reach $39.00 Billion, Globally, by 2032 at…

Prime Determinants of Growth Prime Determinants of Growth The global pharmaceutical warehousing market has experienced significant growth and transformation, driven by a combination of increase in demand from the e-commerce industry and surge in demand for reverse logistics. Pharmaceutical warehousing provides optimal storage for temperature, light & humidity sensitive medications, thus allowing a seamless flow of medication to the end user. Moreover, technological growth in the...
PR Newswire
02/05/2024

PureHealth Delivers Triple Digit Net Profit Growth to USD 134 Million with…

Commenting on the results the Group's Chairman, Hamad Al Hammadi, said: "PureHealth's performance is setting us on a path to joining the ranks of top-tier global healthcare providers. The dedication of our employees is the cornerstone of this success, and their efforts continue to fuel our expansion across the UAE and internationally. We are committed to maintaining this momentum and driving further advancements in pursuit of our mission to advance the science of longevity in the years to…
PR Newswire
02/05/2024

Compass Pathways establishes research collaboration with Mindful Health…

MHS offers comprehensive mental health care services for patients living with TRD and other mental health conditions. They focus on early adoption of advanced, interventional treatment options, as part of a long-term, holistic care model that includes medication management and psychotherapy. MHS operates over 20 outpatient clinics located across California, Washington, Texas, and Georgia.“It is crucial that we understand how different mental health service providers are positioned to...
Nasdaq GlobeNewswire
02/05/2024

AI In Life Science Analytics Market worth $3.56 Bn by 2031 - Exclusive Report by…

Request for Sample Pages: https://www.insightaceanalytic.com/request-sample/2456 Request for Sample Pages:https://www.insightaceanalytic.com/request-sample/2456 AI in the context of life science analytics refers to the use of AI techniques and tools for the analysis of biological as well as environmental data. With the use of artificial intelligence (AI), life science analytics may make better use of complex healthcare, medical, and scientific information by applying high-level...
PR Newswire
02/05/2024

In Vitro Diagnostic (IVD) Reagents Market worth $113.15 Bn by 2031 - Exclusive…

Request for Sample Pages: https://www.insightaceanalytic.com/request-sample/2452 Request for Sample Pages:https://www.insightaceanalytic.com/request-sample/2452 In vitro diagnostic (IVD) reagents are essential components of medical tests that aid in the detection of diseases and other health concerns, allowing for the improvement of treatment decisions. They help monitor the patient's vitals and are utilized for precise diagnostic testing of illnesses and other underlying conditions...
PR Newswire
02/05/2024

The Galien Foundation's Prix Galien UK Forum Returns to London in May 2024

This year's lineup will feature the following panels: This year's lineup will feature the following panels: 9:40 AM–10:40 AMPANEL 1: No decision for me without me: Putting patients at the heart of drug development CHAIRDrMel Walker, Life Sciences Strategic Advisor and Managing Director, BioPharma Futures PANELISTS Robyn Bent, Director of CDER's Patient-Focused Drug Development (PFDD) Program, FDA DrSarah Gheuens, Chief Medical Officer, Head of R&D, Agios...
PR Newswire
02/05/2024

Together with Siemens Healthineers, Varian Showcases Commitment to Embracing…

"As part of Siemens Healthineers, Varian is in a unique position to develop cutting-edge products and solutions that bridge the care gap globally," remarked Arthur Kaindl, Head of Varian. "By combining the expertise of the leading imaging and radiotherapy companies, we have the ability to achieve much more than any individual cancer care company by driving connection throughout the entire care continuum." "As part of Siemens Healthineers, Varian is in a unique position…
PR Newswire
02/05/2024

Last day of trading in unit rights in SciBase rights issue

Summary of the Rights Issue Summary of the Rights Issue ProspectusComplete information regarding the Rights Issue and information about the Company can be found in the prospectus published on19 April 2024. The prospectus is available on the Company's website ( http://investors.scibase.se/en ), on Vator Securities' website ( www.vatorsecurities.se ) and on the Swedish Financial Supervisory Authority's website ( www.fi.se ). Timetable for the Rights Issue Advisors Vator...
PR Newswire
02/05/2024

SciBase supports clinicians during US Skin Cancer Awareness Month

"Melanoma is one of the top 10 most common cancers in the US. With melanoma, early detection is vital to improving clinical outcomes for patients. For these reasons, I am using the AI-powered Nevisense test in my clinical practice. I recently performed a Nevisense test on a mole that I was hesitant to biopsy, and the technology provided me with real-time, non-invasive data right there during that visit. I immediately integrated the Nevisense data into my biopsy decision, and detected a…
PR Newswire
02/05/2024

Implantica's RefluxStop™ is now available in seven hospitals in Spain adding two…

"It's a new day we've long awaited in the world of surgical GERD treatment," says Dra. Guil. She continues, "I'm pleased to see that RefluxStop does not encircle the food passageway and restores the body's natural physiology. RefluxStop allows me to offer a durable treatment for GERD to an entirely new group of patients who weren't previously candidates for surgery." Dra. Guil will be the first to offer RefluxStop in the Canary Islands. "It's a new day we've long awaited…
PR Newswire
02/05/2024

Director/PDMR Shareholding

DXS INTERNATIONAL PLC Notification of Director / PDMR DealingThe Board of DXS International plc (the “Company”), the AQSE Growth Market quoted clinical decision support developer and supplier of clinical decision support systems has received notification that on 30 April 2024 Mr Bob Sutcliffe, tha Chairman, purchased a total of 100,000 Ordinary Shares in the Company at a price of 1.46p per share.Following this transaction Mr Sutcliffe and his wife's interest in DXS Ordinary Shares is...
Nasdaq GlobeNewswire
02/05/2024

Novo Nordisk's sales increased by 22% in Danish kroner and by 24% at constant…

Bagsværd, Denmark, 2 May 2024 - financial report for the period 1 January 2024 to 31 March 2024 Operating profit increased by 27% in Danish kroner and by 30% at constant exchange rates (CER) to DKK 31.8 billion.Sales in North America Operations increased by 34% in Danish kroner (35% at CER). Sales growth in the US was positively impacted by gross-to-net sales adjustments related to prior years. Sales in International Operations increased by 8% in Danish kroner (11% at CER).Sales within...
Nasdaq GlobeNewswire
02/05/2024

Ipsen appoints Keira Driansky as EVP, President of North America

PARIS, FRANCE, 2 May 2024 -Ipsen (Euronext: IPN; ADR: IPSEY), a global specialty-driven biopharmaceutical company, announced today the appointment of Keira Driansky as EVP, President of North America, effective May 13, 2024. She will serve on the Executive Leadership Team (ELT) and report directly to Ipsen's Chief Executive Officer (CEO), David Loew.“We are thrilled to welcome Keira to Ipsen as our new President of North America as she brings extensive experience in the life sciences...
Nasdaq GlobeNewswire
02/05/2024

ONWARD® Medical Convocation of the 2024 Annual General Meeting of Shareholders…

The resolutions, proposed by the Board, to be submitted for adoption at the AGM, are as follows: Adoption of the Company's statutory annual accounts for the financial year ended December 31, 2023, prepared in accordance with International Financial Reporting Standards (IFRS-EU). The 2023 statutory accounts were filed with the Netherlands Authority for the Financial Markets (AFM) on April 25, 2024, and are posted on the Company's website ( www.ir.onwd.com ) and the AFM's website ( afm.nl )...
Nasdaq GlobeNewswire
02/05/2024

Press Release: Beyfortus real-world evidence published in The Lancet shows 82%…

Beyfortus real-world evidence published in The Lancet shows 82% reduction in infant RSV hospitalizationsNew real-world evidence shows Beyfortus (nirsevimab) substantially reduced RSV lower respiratory tract disease and hospitalizations in infants during the 2023-2024 RSV season, versus no intervention 1-6 Results add to the consistent high efficacy of Beyfortus against medically attended RSV lower respiratory tract disease, shown in the pivotal clinical studies and the outcomes from...
Nasdaq GlobeNewswire
02/05/2024

IBA signs contract with Yale New Haven Health and Hartford HealthCare to install…

Louvain-La-Neuve, Belgium, 2 May 2024- IBA (Ion Beam Applications S.A., EURONEXT), the world leader in particle accelerator technology, today announces that it has signed a contract with the Connecticut Proton Therapy Center, a collaboration between Yale New Haven Health, Hartford HealthCare and Proton International, for the installation of a Proteus ® ONE 1 compact proton therapy system. The contract includes a multi-year operation and maintenance agreement, and it is expected that the...
Nasdaq GlobeNewswire
02/05/2024

dsm-firmenich Q1 2024 trading update

Q1 2024 highlights Q1 2024 highlights Dimitri de Vreeze, CEO, commented:"We are pleased to see a more positive market environment and the return of volume growth in our business, together with a further sequential step up in margin. This is most evident for Perfumery & Beauty and Taste, Texture & Health, while we also expect a better momentum developing for Health, Nutrition & Care. Animal Nutrition & Health saw early signs of improving demand and vitamin prices...
PR Newswire
02/05/2024
Altri  Comunicati